St. Gallen, Switzerland (ots/PRNewswire) - - Promising News for Breast Cancer Patients - Web Cast Briefing Available at http://www.ibcsg.org/index.shtm WHAT: BIG 1-98: First results and implications. A landmark, independent study found that letrozole, a leading aromatase inhibitor also known as Femara, demonstrated ...
Edmonton, Canada (ots/PRNewswire) - Isotechnika Inc. announced today that the Company has completed recruitment for its Canadian Phase III psoriasis trial for its lead immunosuppressive compound, ISA247. Of the 400 subjects enrolled in the trial, 207 subjects have commenced treatment. The Company received a "No Objection Letter" from Health Canada on December 1, 2004 and commenced the trial on December 2, 2004. ...
Rochester, New York (ots/PRNewswire) - - Acquisition Broadens Kodak's CR Portfolio; Provides Foundation for Continued Growth - With Photo Eastman Kodak Company today announced it has entered into an agreement to acquire OREX Computed Radiography Ltd., a leading provider of compact, robust computed radiography systems that enable medical practitioners to ...
Madrid, Spain (ots/PRNewswire) - PharmaMar announced today that Zalypsis(R) (PM00104/50), its fifth new marine derived compound, has begun Phase I clinical trials, already in patients, for the treatment of solid tumours. Zalypsis is a novel chemical entity related to the marine natural compounds Jorumycin and the family of Renieramycins, obtained from molluscs ...
Paris (ots/PRNewswire) - - Menactra Vaccine is Safe and Effective in Preventing Potentially Deadly Meningococcal Disease Sanofi pasteur, the vaccines business of the sanofi-aventis Group, announced today that the U.S. Food and Drug Administration (FDA) has licensed Menactra(TM) (Meningococcal [Groups A, ...
Basel, Switzerland (ots/PRNewswire) - - First Treatment of its Kind With Proven Survival Benefit for Patients With Advanced Colorectal Cancer Roche today announced that the European Commission has approved Avastin (bevacizumab, rhuMAb-VEGF), the new innovative anti-angiogenesis drug, for the treatment of patients with previously untreated metastatic colorectal cancer. Roche will now make Avastin available ...
Queensland, Australia (ots/PRNewswire) - The people of Nias and surrounding islands have been some of the worst affected by the Earthquake Tsunami disaster that struck on 26 December. Nias lies around 125 km off the west coast of Northern Sumatra in Indonesia and, similar to Banda Aceh, encountered the full force of the Earthquake and Tsunami. Local reports ...
Graduate Management Admission Council
Mclean, Virginia (ots/PRNewswire) - In a precedent-setting decision released on December 27, 2004, the Beijing High Court (the highest court in Beijing, China) has ruled in favor of the Graduate Management Admission Council(R) in the Council's copyright infringement suit against the Beijing New Oriental School (BNOS). The case is one of the first intellectual ...
Phuket, Thailand (ots/PRNewswire) - The Thai government is in the process of establishing an international standard post mortem and ante-mortem identification centre in Phuket as the processing of victims of the tsunami that hit Thailand gets underway. There are now disaster victim identification (DVI) teams from 19 countries in Thailand working under the command of General Nopadol of the Royal Thai Police, the ...
Zurich, Switzerland (ots/PRNewswire) - Baxter Healthcare S.A. announced today that the European Commission has granted expanded approval of ADVATE(R) (Octocog Alfa Recombinant Coagulation Factor VIII), for use in children with haemophilia A under six years of age. This expanded approval was granted on the ...
Abbott Park, Illinois (ots/PRNewswire) - - HUMIRA Data Shows Slowed Joint Damage in Pivotal Study Abbott (NYSE: ABT) announced it has simultaneously submitted a Type II Variation to the European Medicines Agency (EMEA) and a supplemental Biologics License Application (sBLA) with the U.S. Food and Drug ...
Abbott Park, Illinois (ots/PRNewswire) - - First expansion into new disease for rheumatoid arthritis drug HUMIRA Abbott (NYSE: ABT) announced it has simultaneously submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMEA) and a supplemental Biologics License Application ...
London (ots/PRNewswire) - AstraZeneca today announced that the initial analysis of the primary endpoint of Study 709, IRESSA Survival Evaluation in Lung cancer (ISEL) with 1692 patients has been conducted, and shows that IRESSA failed to significantly prolong survival in comparison to placebo in the overall ...
London (ots/PRNewswire) - - 'Redefining Hope and Beauty' Campaign Surpasses All Expectations Breast cancer charities from around the world are today celebrating the success of the world's first truly global breast cancer awareness campaign - 'Redefining Hope and Beauty'. In the first few weeks since its historic launch, the campaign has already surpassed ...
San Antonio Breast Cancer Symposium, California (ots/PRNewswire) - - New Results From Two Phase II Trials Demonstrate Efficacy and Tolerability for 'Faslodex' Following Progression on aromatase Inhibitor Therapy - Webcast of Data Available on www.astrazenecapressoffice.com Important new data from two studies presented at the 27th Annual San Antonio Breast ...
San Antonio, Texas (ots/PRNewswire) - - New Trial Results Offer More Choice for More Women With Breast Cancer The ATAC ('Arimidex', Tamoxifen, Alone or in Combination) Completed Treatment Analysis(1),(2): Presented by Professor Anthony Howell and simultaneously published via fast-track peer-review in ...
San Antonio, Texas (ots/PRNewswire) - - 'The Latest Hormonal Treatment Options in the Breast Cancer Continuum' - An AstraZeneca Sponsored Webcast From the 2004 San Antonio Breast Cancer Symposium This webcast will announce key new data for 'FASLODEX' and 'ARIMIDEX' that is being presented at the 27th San Antonio Breast Cancer Symposium (SABCS), 8 - 11 December. The webcast explores the latest developments in the treatment of postmenopausal women with early ...
Laval, Quebec (ots/PRNewswire) - LAB International Inc. (TSX: LAB, Frankfurt: LD9.F, XETRA: LD9.DE), an integrated drug development company focused on the inhalation market, today announced that its shares are available for trading on the Regulated Unofficial Market (Freiverkehr) of the Frankfurt Stock Exchange and on XETRA(R), the Deutsche Borse AG electronic trading system. The inclusion of LAB's securities in the ...
Deerfield, Illinois (ots/PRNewswire) - Baxter International Inc. (NYSE: BAX) announced today that it has voluntarily suspended enrollment in the Phase II/III clinical study currently underway in Europe of its PreFluCel influenza vaccine, due to a higher than expected rate of mild fever and associated symptoms in the clinical trial participants. "In developing a ...
Austrian Breast and Colorectal Cancer St
San Antonio, Texas (ots) - - First Data from Large Trial in Premenopausal Women Show Strong Protective Effect Zoledronic acid prevents loss of bone mass caused by adjuvant treatment with an aromatase inhibitor or tamoxifen and the luteinising hormone-releasing hormone analog (LHRHa) goserelin ...
London (ots/PRNewswire) - Medicsight Inc. (OTC Bulletin Board: MSHT) announced today that on November 30, 2004 it forwarded its application to transfer the Company's listing from the OTC Bulletin Board to the American Stock Exchange to Cohen Specialists LLC, who deposited it with the American Stock Exchange on ...
Austrian Breast and Colorectal Cancer St
San Antonio (ots) - - First Data from Large Trial in Premenopausal Women Show Strong Protective Effect Zoledronic acid prevents loss of bone mass caused by adjuvant treatment with an aromatase inhibitor or tamoxifen and the luteinising hormone-releasing hormone analog (LHRHa) goserelin ...
Laval, Canada (ots/PRNewswire) - - Malnutrition in Patients With Late Pre-end-stage Chronic Renal Failure Selected as Clinical Indication for Trial LAB International Inc. (TSX: LAB), an integrated drug development company focused on the inhalation market, today announced that, after completion of a successful dose-response trial, it has selected the first clinical indication for which it intends to evaluate ...
London (ots/PRNewswire) - - Spontaneity and Self-Confidence Cited as Reasons Why Men Preferred Cialis In Second Study A recent analysis demonstrated that 80 percent of men who took 20 mg Cialis(R)(1) (tadalafil) for the treatment of erectile dysfunction (ED) and had successful intercourse reported ...
London (ots/PRNewswire) - - Patients with moderate-to-severe ED and comorbid conditions respond to Cialis Cialis(R)(1) (tadalafil) may effectively treat erectile dysfunction (ED) in men with a variety of comorbidities that can make the condition more difficult to manage, according to new studies released ...
Moulin International Holdings Limited
Hong Kong (ots/PRNewswire) - - Integrates the Largest Frame Manufacturer in Asia with the Most Powerful Value Proposition in the US Retail Market Moulin International Holdings Limited ("Moulin" / the "Group")(stock code: 389), a global leader in the manufacturing, distribution and retailing of eyewear, ...
Edmonton, Alberta (ots/PRNewswire) - Isotechnika Inc. announced today that a Canadian Phase III trial for its lead immunosuppressive drug candidate, ISA247 for the treatment of moderate to severe psoriasis has commenced. As of today, a total of 21 patients have been enrolled and dosing has begun. The Phase III trial will be performed over a twenty-four week period at thirty-three centers across Canada involving a ...
Edmonton, Alberta (ots/PRNewswire) - Isotechnika Inc. announced today that the Company received a No Objection Letter from Health Canada for the commencement of a Phase III trial for its lead immunosuppressive drug candidate, ISA247. The trial will be performed over a twenty-four week period at thirty- ...
Tampere, Finland and London (ots/PRNewswire) - Inion, a rapidly growing company focused on the development of novel biodegradable medical implants, is very pleased to announce that its ordinary shares have been admitted to the Official List of the UK Listing Authority and will begin unconditional trading today on London's Main Market under the symbol IIN.L. The Company's listing in London takes place in connection ...
Basel, Switzerland, November 30 (ots/PRNewswire) - Roche and Genentech, Inc., announced today that Avastin(TM) (bevacizumab, rhuMAb-VEGF), a new innovative anti-angiogenesis drug, has shown for the first time that it significantly increases survival in patients with metastatic colorectal cancer when used in ...